“Completing the first case with RECELL GO at the Joseph M. Still Burn Center is a defining moment for AVITA Medical,” said
"As the largest
RECELL technology offers clinicians and their patients a range of benefits compared to traditional skin grafting. The innovative device allows for improved healing using significantly less donor skin1, leading to reduced pain, faster closure, and enhanced aesthetic appearance.2 Additionally, patients often require fewer procedures for definitive closure and experience a reduced length of stay for burns covering less than 50% total body surface area.2,3,4
RECELL GO introduces enhanced features that streamline the preparation of Spray-On Skin™ Cells. This next-generation device significantly reduces the training burden on medical staff, improves workflow efficiency in the operating room, and controls the RECELL Enzyme™ incubation time to ensure optimal cell yield and viability. These advancements simplify the user interface, enabling medical teams to provide quality care readily and consistently to their patients.
About
In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including burns, full-thickness skin defects, and vitiligo. The RECELL System is TGA-registered in
To learn more, visit www.avitamedical.com.
Forward-Looking Statements
Statements in this announcement may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements generally may be identified by the use of words such as “anticipate,” “expect,” “intend,” “could,” “may,” “will,” “believe,” “estimate,” “look forward,” “forecast,” “goal,” “target,” “project,” “continue,” “outlook,” “guidance,” “future,” and similar words or expressions, and the use of future dates. Forward-looking statements in this announcement include but are not limited to statements concerning our product development activities, regulatory approval of our products, the potential for future growth of our business, and our ability to achieve financial goals. These statements are made as of the date of this announcement, and the Company undertakes no obligation to publicly update or revise any of these statements, except as required by law. For additional information and other important factors that may cause actual results to differ materially from forward-looking statements, please see the “Risk Factors” section of the Company’s latest Annual Report on Form 10-K and other publicly available filings for a discussion of these and other risks and uncertainties.
Authorized for release by the Chief Financial Officer of
1 Instructions for Use. RECELL® Autologous Cell Harvesting Device.
2 Holmes JH, Molnar JA, Carter JE, et al. A comparative study of the RECELL® device and autologous split-thickness meshed skin graft in the treatment of acute burn injuries. J Burn Care Res. 2018;39(5):694-702.
3 Kowal S, Kruger E, Bilir P, et al. Cost effectiveness of the use of autologous cell harvesting device compared to standard of care for treatment of severe burns in
4 Holmes JH, Molnar JA, Carter JE, et al. A comparative study of the RECELL® device and autologous split-thickness meshed skin graft in the treatment of acute burn injuries. J Burn Care Res. 2018;39(5):694-702.
![](https://ml.globenewswire.com/media/MDI0NGNkMzctMWM2Yi00ZTAyLWE5ZjEtZDYxNDViYWVhMTU0LTExOTMwNzk=/tiny/AVITA-Medical.png)
Investor & Media Contact:Jessica Ekeberg Phone +1-661-904-9269 investor@avitamedical.com media@avitamedical.com
2024 GlobeNewswire, Inc., source